Q2 Earnings Estimate for TOI Issued By B. Riley

The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) - Investment analysts at B. Riley issued their Q2 2025 earnings estimates for Oncology Institute in a report issued on Tuesday, July 15th. B. Riley analyst Y. Zhi forecasts that the company will post earnings of ($0.13) per share for the quarter. B. Riley has a "Strong-Buy" rating on the stock. B. Riley also issued estimates for Oncology Institute's Q3 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.55) EPS and FY2025 earnings at ($0.55) EPS.

Separately, BTIG Research assumed coverage on Oncology Institute in a research note on Thursday, May 15th. They set a "buy" rating and a $7.00 price objective on the stock.

Oncology Institute Price Performance

TOI stock opened at $3.65 on Friday. The company has a quick ratio of 1.59, a current ratio of 1.79 and a debt-to-equity ratio of 14.58. Oncology Institute has a fifty-two week low of $0.13 and a fifty-two week high of $3.83. The business has a 50 day moving average price of $2.73 and a 200 day moving average price of $1.73. The stock has a market cap of $325.69 million, a price-to-earnings ratio of -5.21 and a beta of 0.02.

Oncology Institute (NASDAQ:TOI - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter. The firm had revenue of $104.41 million during the quarter. Oncology Institute had a negative net margin of 15.38% and a negative return on equity of 445.02%.

Insider Activity at Oncology Institute

In other Oncology Institute news, Director Growth I. L.P. M33 sold 76,324 shares of the stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $3.05, for a total value of $232,788.20. Following the transaction, the director directly owned 1,272,724 shares in the company, valued at approximately $3,881,808.20. This trade represents a 5.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brad Hively sold 1,976,137 shares of Oncology Institute stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $2.87, for a total value of $5,671,513.19. Following the completion of the sale, the director directly owned 603,501 shares in the company, valued at $1,732,047.87. This represents a 76.61% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,726,137 shares of company stock valued at $13,379,013. 8.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Jane Street Group LLC grew its holdings in Oncology Institute by 613.6% during the 4th quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock worth $39,000 after acquiring an additional 109,769 shares during the period. Virtu Financial LLC acquired a new position in Oncology Institute during the 4th quarter valued at about $41,000. Renaissance Technologies LLC boosted its stake in Oncology Institute by 7.1% during the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock valued at $56,000 after purchasing an additional 12,000 shares during the last quarter. XTX Topco Ltd lifted its position in shares of Oncology Institute by 49.5% during the 1st quarter. XTX Topco Ltd now owns 55,698 shares of the company's stock worth $63,000 after buying an additional 18,448 shares in the last quarter. Finally, Citizens Financial Group Inc. RI bought a new position in shares of Oncology Institute during the 1st quarter worth approximately $71,000. 36.86% of the stock is owned by institutional investors.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.